Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript
Inspire Medical Systems (INSP) reported Q2 2026 revenue of $200.6 million, down 7.6% year over year, citing coding and reimbursement disruptions. Adjusted diluted EPS was $0.14 versus $0.34 a year earlier. Management raised full-year revenue guidance to $835 million to $875 million and estimated a $40 million Q2 adverse impact, with $120 million to $130 million for the year.
How this was made
The 30-second read
Why it matters
Traders can update models using the explicit FY 2026 revenue guidance raise, quantified reimbursement headwinds (Q2 and full-year), and the stated Q3 revenue decline expectation, plus margin and cash flow guidance elements.
Market read
The newest tradable inputs are the raised FY 2026 revenue guidance, the quantified coding and reimbursement headwind, and the Q3 revenue forecast decline, which together define the near-term risk premium.
What to watch
The call flags vendor production equipment impairments and restructuring charges timing (mostly Q3), which could create additional volatility in reported GAAP results beyond the adjusted metrics.
Background
The article is a transcript-style summary of Inspire Medical Systems’ Q2 2026 earnings call, centered on coding and reimbursement disruptions for its Inspire V system and management’s mitigation plan (Project Horizon).
Ticker impact
Inspire Medical Systems raised full-year 2026 revenue guidance to $835M-$875M while estimating a $40M Q2 coding and reimbursement headwind.
Likely choppy reaction: upside from raised full-year revenue guidance, offset by Q3 decline and ongoing coding/reimbursement uncertainty.
The article provides multiple decision-relevant datapoints: raised FY revenue range, quantified adverse impact ($40M Q2, $120M-$130M FY), and an 8%-10% YoY Q3 revenue decline expectation, which together shape near-term risk/reward.
Market effects
Highlights reimbursement and coding disruption risk as a key swing factor for neurostimulation device makers, with margin sensitivity to sales mix and prior authorization tooling.
Notes Continental Europe expansion, especially Germany, and France reimbursement changes, which may support regional demand durability despite US coding headwinds.
CMS-proposed 2027 facility and ASC reimbursement increases could improve medium-term US reimbursement expectations for the category, partially offsetting current MAC-related modifier pressure.
Counterpoint
The raised FY revenue range may be more than offset by the magnitude of the estimated reimbursement headwind and the expectation of breakeven adjusted operating income due to higher marketing spend.
Key entities
- companyInspire Medical Systems, Inc.
Subject of the earnings call, reporting Q2 results and updating full-year 2026 guidance amid coding and reimbursement disruptions.
- regulatorCMS
Proposed 2027 reimbursement rates referenced as a supportive factor for facility and ASC reimbursement assumptions.
- payerMACs
Medicare Administrative Contractors cited as requiring a modifier, with payment reductions ranging up to 30% of the national Medicare average in certain regions.
